Literature DB >> 21170906

An exact method for analysis following a two-stage phase II cancer clinical trial.

Gordana Jovic1, John Whitehead.   

Abstract

This paper presents an exact method for the analysis of a phase II cancer clinical trial conducted using a two-stage design in which early stopping may be allowed for either futility or efficacy. The method provides a point and interval estimate of the response probability associated with the treatment under investigation and a p-value for testing whether this exceeds some standard null value. Two-stage designs are often used in phase II trials in oncology for reasons of ethics and efficiency, but this design feature is seldom taken into account when the results are analyzed. After any two-stage design or multi-stage design, the method for analysis should take into account the previous interim analyses performed, otherwise the results will be biased. In this paper, an approximate approach based on a log-odds ratio parameterisation will be compared with an exact method through the calculation of the precise coverage probabilities of each approach.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 21170906     DOI: 10.1002/sim.3837

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  11 in total

1.  Two-stage design for phase II oncology trials with relaxed futility stopping.

Authors:  Anastasia Ivanova; Allison M Deal
Journal:  Stat Interface       Date:  2015-10-22       Impact factor: 0.582

2.  Identifying combined design and analysis procedures in two-stage trials with a binary end point.

Authors:  Jack Bowden; James Wason
Journal:  Stat Med       Date:  2012-07-11       Impact factor: 2.373

3.  Correcting for bias in the selection and validation of informative diagnostic tests.

Authors:  David S Robertson; A Toby Prevost; Jack Bowden
Journal:  Stat Med       Date:  2015-02-01       Impact factor: 2.373

4.  Evaluating clinical trial designs for investigational treatments of Ebola virus disease.

Authors:  Ben S Cooper; Maciej F Boni; Wirichada Pan-ngum; Nicholas P J Day; Peter W Horby; Piero Olliaro; Trudie Lang; Nicholas J White; Lisa J White; John Whitehead
Journal:  PLoS Med       Date:  2015-04-14       Impact factor: 11.069

5.  Efficient confidence limits for adaptive one-arm two-stage clinical trials with binary endpoints.

Authors:  Guogen Shan; Hua Zhang; Tao Jiang
Journal:  BMC Med Res Methodol       Date:  2017-02-06       Impact factor: 4.615

6.  Adaptive designs in clinical trials: why use them, and how to run and report them.

Authors:  Philip Pallmann; Alun W Bedding; Babak Choodari-Oskooei; Munyaradzi Dimairo; Laura Flight; Lisa V Hampson; Jane Holmes; Adrian P Mander; Lang'o Odondi; Matthew R Sydes; Sofía S Villar; James M S Wason; Christopher J Weir; Graham M Wheeler; Christina Yap; Thomas Jaki
Journal:  BMC Med       Date:  2018-02-28       Impact factor: 8.775

7.  A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial).

Authors:  Athimalaipet V Ramanan; Andrew D Dick; Ashley P Jones; Catherine Guly; Ben Hardwick; Helen Hickey; Richard Lee; Andrew McKay; Michael W Beresford
Journal:  BMC Rheumatol       Date:  2018-02-27

8.  Trial design for evaluating novel treatments during an outbreak of an infectious disease.

Authors:  John Whitehead; Piero Olliaro; Trudie Lang; Peter Horby
Journal:  Clin Trials       Date:  2016-01-14       Impact factor: 2.486

9.  What inference for two-stage phase II trials?

Authors:  Raphaël Porcher; Kristell Desseaux
Journal:  BMC Med Res Methodol       Date:  2012-08-06       Impact factor: 4.615

10.  Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial.

Authors:  Jake Dunning; Foday Sahr; Amanda Rojek; Fiona Gannon; Gail Carson; Baimba Idriss; Thomas Massaquoi; Regina Gandi; Sebatu Joseph; Hassan K Osman; Timothy J G Brooks; Andrew J H Simpson; Ian Goodfellow; Lucy Thorne; Armando Arias; Laura Merson; Lyndsey Castle; Rebecca Howell-Jones; Raul Pardinaz-Solis; Benjamin Hope-Gill; Mauricio Ferri; Jennifer Grove; Mark Kowalski; Kasia Stepniewska; Trudie Lang; John Whitehead; Piero Olliaro; Mohammed Samai; Peter W Horby
Journal:  PLoS Med       Date:  2016-04-19       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.